Sanofi’s Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA’s Approval for the Treatment of R/R Multiple Myeloma

 Sanofi’s Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA’s Approval for the Treatment of R/R Multiple Myeloma

Sanofi’s Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA’s Approval for the Treatment of R/R Multiple Myeloma

Shots:

  • The approval is based on P-III IKEMA study involves assessing of Sarclisa + carfilzomib and dexamethasone(kd) vs SOC in 302 patients with RRMM who had received 1 to 3 prior lines of treatment
  • The result demonstrated a reduction in the risk of disease progression or death by 45%. At pre-planned interim analysis, median PFS is not yet reached, ORR (86.6% vs 82.9%), CR (39.7% vs 27.6%), VGPR rate (33% vs 28.5%), OS were still immature
  • The FDA marks the second approval for Sarclisa, also approved in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with RRM

Click here to­ read full press release/ article | Ref: Sanofi | Image: Evaluate Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post